Log in

2563 Beijing Biostar Pharmaceuticals Co., Ltd. HKEX · China

Beijing Biostar Pharmaceuticals Co. (2563) news

Beijing Biostar Pharmaceuticals Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2563, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Beijing Biostar Pharmaceuticals Co. news

We have not published a story on Beijing Biostar Pharmaceuticals Co. yet. When there is news, it will appear here.

Questions about Beijing Biostar Pharmaceuticals Co.

What is the ticker symbol of Beijing Biostar Pharmaceuticals Co.?

Beijing Biostar Pharmaceuticals Co., Ltd. trades under the ticker 2563 on HKEX.

Where is Beijing Biostar Pharmaceuticals Co. listed?

Beijing Biostar Pharmaceuticals Co., Ltd. is listed on HKEX.

Which country or territory is Beijing Biostar Pharmaceuticals Co. listed under?

Our directory records Beijing Biostar Pharmaceuticals Co., Ltd. under China.

What does Beijing Biostar Pharmaceuticals Co. do?

Our directory classifies Beijing Biostar Pharmaceuticals Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Beijing Biostar Pharmaceuticals Co.?

The ISIN recorded for Beijing Biostar Pharmaceuticals Co., Ltd. is CNE100006NB3.

Does aibio.space cover Beijing Biostar Pharmaceuticals Co.?

aibio.space lists Beijing Biostar Pharmaceuticals Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Beijing Biostar Pharmaceuticals Co.?

Companies in our directory listed in the same country and business area as Beijing Biostar Pharmaceuticals Co.: Hanshang Group Co., Guizhou Bailing Group Pharmaceutical Co., Zhejiang Shengda Bio-Pharm Co., Golden Throat Holdings Group Co, Hinova Pharmaceuticals, Guangzhou Baiyunshan Pharmaceutical Holdings Company.

Investor discussion: Beijing Biostar Pharmaceuticals Co.

Members talk about Beijing Biostar Pharmaceuticals Co. (2563). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Beijing Biostar Pharmaceuticals Co., newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source

  2. Financings

    Share or debt issue: (1) 2025 ANNUAL RESULTS & DIVIDEND; (2) CONNECTED TRANSACTIONS; (3) APPOINTMENT OF DIRECTOR & AUDITOR; (4) GENERAL & REPURCHASE MANDATES; (5) CANCELLATION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO ARTICLES OF ASSOCIATION; (6) SHARE OPTION SCHEME; AND NOTICE OF THE ANNUAL GENERAL MEETING. Source

  3. Financings

    Share or debt issue: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source

  4. Financings

    Share or debt issue: SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source

  5. Financings

    Share or debt issue: (1) 2024 REPORT OF THE BOARD; (2) 2024 REPORT OF THE SUPERVISORY COMMITTEE; (3) 2024 AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (4) 2024 ANNUAL REPORT; (5) PROFIT DISTRIBUTION PLAN OF THE COMPANY FOR THE YEAR 2024; (6) REMUNERATION OF DIRECTORS FOR THE YEAR 2025; (7) REMUNERATION OF SUPERVISORS FOR THE YEAR 2025; (8) PROPOSED APPOINTMENT OF AUDITOR FOR 2025; (9) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES; AND NOTICE OF THE ANNUAL GENERAL MEETING. Source

  6. Listings

    Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source

  7. Listings

    Trading status: (1) QUARTERLY UPDATE ON STATUS OF RESUMPTION; AND (2) RESUMPTION OF TRADING. Source

  8. Listings

    Trading status: EXCHANGE NOTICE - SUSPENSION OF TRADING. Source

  9. Listings

    Trading status: DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS; AND POSSIBLE SUSPENSION OF TRADING. Source

Press releases

Headlines of Beijing Biostar Pharmaceuticals Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UTD2 OF BIOSTAR ACHIEVES FIRST PATIENT DOSING IN PHASE III CLINICAL STUDY FOR HER2-NEGATIVE ADVANCED BREAST CANCER

  2. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  3. HKEXnews

    COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

  4. HKEXnews

    POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026

  5. HKEXnews

    SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

  6. HKEXnews

    SUPPLEMENTAL CIRCULAR (1) CLARIFICATION AND WITHDRAWAL OF ORDINARY RESOLUTION IN RELATION TO THE CONNECTED TRANSACTION; (2) PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026; (3) WITHDRAWAL OF SPECIAL RESOLUTIONS IN RELATION TO SHARE OPTION SCHEME; AND SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

  7. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  8. HKEXnews

    (1) 2025 ANNUAL RESULTS & DIVIDEND; (2) CONNECTED TRANSACTIONS; (3) APPOINTMENT OF DIRECTOR & AUDITOR; (4) GENERAL & REPURCHASE MANDATES; (5) CANCELLATION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO ARTICLES OF ASSOCIATION; (6) SHARE OPTION SCHEME; AND NOTICE OF THE ANNUAL GENERAL MEETING

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - FOUR CLINICAL STUDY RESULTS OF UTIDELONE OF BIOSTAR PHARMACEUTICALS SELECTED FOR THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

  10. HKEXnews

    CLARIFICATION ANNOUNCEMENT IN RELATION TO PROPOSED ADOPTION OF SHARE OPTION SCHEME

  11. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

  12. HKEXnews

    PROPOSED ADOPTION OF SHARE OPTION SCHEME AND PROPOSED MANDATE TO THE BOARD AND/OR AUTHORISED PERSON TO HANDLE MATTERS PERTAINING TO THE SHARE OPTION SCHEME

  13. HKEXnews

    SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

  15. HKEXnews

    RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; NON-COMPLIANCE WITH THE LISTING RULES; AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

  16. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

  17. HKEXnews

    INSIDE INFORMATION - LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE FULL CIRCULATION OF SHARES BY THE COMPANY

  18. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO EXPECTED QUALIFIED OPINION

  19. HKEXnews

    INSIDE INFORMATION - EXPECTED QUALIFIED OPINION

  20. HKEXnews

    INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE FULL CIRCULATION OF SHARES BY THE COMPANY

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2563 on TradingView.

Listing details

Beijing Biostar Pharmaceuticals Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2563, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Beijing Biostar Pharmaceuticals Co., Ltd.
Ticker
2563
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE100006NB3
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.